Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.54 |
| ▸ | KDR | P35968 | 18/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 3/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.40 |
| ▸ | TEK | Q02763 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL574211 | 0.99 | NTRK1 (0.55) | NTRK1KDRRETEPHB2BRAF | |
| SCHEMBL574065 | 0.94 | NTRK1 (0.54) | NTRK1KDRRETEPHB2BRAF | |
| SCHEMBL574399 | 0.93 | NTRK1 (0.53) | NTRK1KDRRETEPHB2BRAF | |
| SCHEMBL574518 | 0.91 | NTRK1 (0.46) | NTRK1KDRRETEPHB2 | |
| SCHEMBL574253 | 0.91 | NTRK1 (0.45) | NTRK1KDRRETEPHB2 | |
| SCHEMBL574608 | 0.91 | NTRK1 (0.46) | NTRK1KDRRETEPHB2 | |
| SCHEMBL574198 | 0.90 | NTRK1 (0.52) | NTRK1KDRRETEPHB2BRAF | |
| SCHEMBL827574 | 0.90 | NTRK1 (0.48) | NTRK1KDRRETEPHB2BRAF | |
| SCHEMBL573816 | 0.90 | NTRK1 (0.46) | NTRK1KDRRETEPHB2 | |
| SCHEMBL574093 | 0.90 | NTRK1 (0.51) | NTRK1KDRRETEPHB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012019015-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | DECIPHERA PHARMACEUTICALS, LLC | 2011-08-04 | — | — | US | disclosed |
| EP-2146716-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008131227-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | MCL1, NRAS, ABL1 | NTRK1 1105/4885KDR 2434/4885RET 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.